← Leaderboards
Tawanda Gumbo
Ut Southwestern Medical Center
$7,928,264
Attributed
$13,251,900
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2007–19$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$13,251,900 · 6
By mechanism
UH3$4,733,613 · 1
R01$4,063,725 · 2
DP2$2,355,000 · 1
UH2$1,199,999 · 1
R56$899,563 · 1
Top collaborators
- Gregory P. Bisson5 shared
- Daniel Kalman5 shared
- Deepak Kaushal5 shared
- Helen Mcilleron5 shared
Others in their field
Top investigators on “Pharmacodynamics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Richard L Schilsky · University Of Chicago$115,275,890
- David Heimbrook · Leidos Biomedical Research, Inc.$109,519,710
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Myron S Cohen · Family Health International$91,263,426
Research focus
PharmacodynamicsDrug KineticsTuberculosis TreatmentBaseResponseDosePharmaceutical PreparationsMycobacterium TuberculosisTuberculosisResistanceRegimenAntitubercular AgentsDesignMoxifloxacinMulti-Drug ResistanceTranslatingInnovationRifampinMutationAntibioticsPyrazinamideDrug CombinationsInfectionClinical Trials
Grant awards (17)
Development of Gleevec for TB and TB/HIV$1,571,205
UH3 · FY2019 · AI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$346,986
R01 · FY2019 · AI
Development of Gleevec for TB and TB/HIV$1,534,659
UH3 · FY2018 · AI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,972
R01 · FY2018 · AI
Development of Gleevec for TB and TB/HIV$1,627,749
UH3 · FY2017 · AI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,914
R01 · FY2017 · AI
Development of Gleevec for TB and TB/HIV$599,999
UH2 · FY2016 · AI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,985
R01 · FY2016 · AI
Development of Gleevec for TB and TB/HIV$600,000
UH2 · FY2015 · AI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,997
R01 · FY2015 · AI
Short course therapy for MDR-TB based on PK/PD answers for biological variability$736,025
R56 · FY2014 · AI · contact PI
Short course therapy for MDR-TB based on PK/PD answers for biological variability$163,538
R56 · FY2014 · AI · contact PI
PK-PD of combination antituberculosis therapy for suppression of drug-resistance$434,222
R01 · FY2011 · AI · contact PI
PK-PD of combination antituberculosis therapy for suppression of drug-resistance$601,501
R01 · FY2010 · AI · contact PI
PK-PD of combination antituberculosis therapy for suppression of drug-resistance$628,273
R01 · FY2009 · AI · contact PI
PK-PD of combination antituberculosis therapy for suppression of drug-resistance$652,875
R01 · FY2008 · AI · contact PI
Efflux pump inhibitors to reduce duration of antituberculosis therapy$2,355,000
DP2 · FY2007 · OD · contact PI